Christopher S Parks, 541362 Battleview Dr NW, Atlanta, GA 30327

6664066, Dec 16, 2003

Dec 16, 2002

10/311582

Christopher L. Parks - Boonton NJ

Wyeth Holdings Corporation - Madison NJ

C12Q 168

435 6, 435 5, 4241841, 4241991, 536 2372

Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.

6673572, Jan 6, 2004

Oct 1, 2002

10/261961

Christopher L. Parks - Boonton NJ
Mohinderjit S. Sidhu - Scotch Plains NJ
Stephen A. Udem - New York NY
Gerald R. Kovacs - Morristown NJ

Wyeth Holdings Corporation - Madison NJ

C12P 2106

435 691, 435 5, 435 6, 435325, 4241921, 4241991

This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV). One method for producing a recombinant virus from the Order Mononegavirales comprises (a) in at least one host cell, conducting transfection of a rescue composition which comprises (i) a transcription vector comprising an isolated nucleic acid molecule which comprises polynucleotide sequence encoding a genome or antigenome of a nonsegmented, negative-sense, single stranded RNA virus of the Order Mononegavirales and (ii) at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins necessary for encapsidation, transcription and replication; in a host cell under conditions sufficient to permit the co-expression of these vectors and the production of the recombinant virus; (b) heating the transfected rescue composition to an effective heat shock temperature under conditions sufficient to increase the recovery of the recombinant virus; and optionally, (c) harvesting the resulting recombinant virus.

2002005, May 9, 2002

May 21, 2001

09/861975

Christopher Parks - Boonton NJ, US
Thomas Shenk - Princeton NJ, US

A61K048/00
C12N015/861

435/456000, 435/320100, 424/093200

Multiple binding sites for the transcription factors MAZ and Sp1 within the adenovirus type 5 major late promoter have been identified by DNase I protection studies. In the proximal region of the promoter, both MAZ and Sp1 interact with GC-rich sequences flanking the TATA box. Two MAZ binding sites are centered at -18 and -36 relative to the transcriptional initiation site. Sp1 bound only to the -18 GC-rich sequence. Several sites of interaction were also evident in the distal region of the promoter. Both MAZ and Sp1 interacted with a sequence centered at -166, and MAZ bound weakly to an additional site centered at -130. Over expression of MAZ or Sp1 activated expression from the major late promoter in transient expression assays. Mutational analysis of the GC-rich sequences in the major late promoter suggested that a primary target of MAZ activation is the GC rich sequences flanking the TATA sequence, whereas Sp1 requires the distal GC-rich sequence elements to stimulate gene expression. This activation is enhanced by the adenovirus E1 A protein, and evidence for interaction between E1 A and both transcription factors was obtained using an immunoprecipitation assay. Activation by MAZ and Sp1 also was observed in transfection studies using the complete adenovirus type 5 genome as the target. Increased levels of late mRNA from both the L1 and L5 regions were observed when MAZ or Sp1 expression plasmids were transfected with viral DNA. Unexpectedly, activation of the major late promoter by MAZ and Sp1 was detected irrespective of whether the viral DNA could replicate.

2005008, Apr 28, 2005

Jun 22, 2001

10/312052

Christopher Parks - Boonton NJ, US
Mohinderjit Sidhu - New City NY, US
Pramila Walpita - Basking Ridge NJ, US
Gerald Kovacs - Ridgewood NJ, US
Stephen Udem - New York NY, US

C12N007/00
C12N015/86

435235100, 435456000

This invention relates to a method for recombinantly producing via rescue canine distemper virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the canine distemper virus as an attenuated and/or infectious viruses. The recombinant viruses can be prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and rearrangements, in the genome can be obtained.

2009016, Jun 25, 2009

Dec 16, 2008

12/335778

Christopher L. Parks - Boonton NJ, US
Susan E. Witko - New City NY, US
Maninder K. Sidhu - New City NY, US
J. Erik Johnson - Verona NJ, US
Roger Michael Hendry - Atlanta GA, US

Wyeth - Madison NJ

A61K 35/76
C12N 7/02
C07H 21/04
A61P 37/00

424 932, 435239, 536 2372

A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) is provided. The method involves providing a cell that includes an optimized VSV G gene, wherein expression of VSV G protein from the optimized VSV G gene is inducible; and inducing the cell to express VSV G protein from the optimized VSV G gene. The method also involves infecting the induced cell with an attenuated VSV; growing the infected cells in culture; and recovering attenuated VSV from the culture.

2009017, Jul 9, 2009

Dec 16, 2008

12/335763

Christopher L. Parks - Boonton NJ, US
Susan E. Witko - New City NY, US
Maninder K. Sidhu - New City NY, US
J. Erik Johnson - Verona NJ, US
Roger Michael Hendry - Atlanta GA, US

Wyeth - Madison NJ

A61K 39/12
C12N 15/09
C12N 15/87
C12N 15/63

4241991, 435455, 435461, 4353201

A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) in a cell culture is provided. The method involves introducing a plasmid vector encoding an optimized VSV G gene into a cell; expressing VSV G protein from the optimized VSV G gene; and introducing a propagation-defective VSV into the cell expressing the VSV G protein encoded by the optimized VSV G gene. The method further includes growing the cells in culture; and recovering the propagation-defective VSV from the culture.

2010021, Aug 26, 2010

Feb 19, 2010

12/708940

Christopher L. PARKS - Boonton NJ, US
Ivo Lorenz - Brooklyn NY, US
Sanjay K. Phogat - Frederick MD, US
Timothy J. Zamb - Nyack NY, US

A61K 39/12
C12N 15/63
C12N 7/08
A61P 31/18

4241991, 4353201, 435237

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

2013012, May 23, 2013

Oct 26, 2012

13/661737

International AIDS Vaccine Initiative - New York NY, US
Micheal J. Caulfield - Fort Washington PA, US
Ivo C. Lorenz - Brooklyn NY, US
Christopher L. Parks - Boonton NJ, US

International AIDS Vaccine Initiative - New York NY

A61K 39/21

4241991

The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.